Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-human, Dose-escalation Followed by Expansion Study to Assess the Safety and Preliminary Efficacy of a Bispecific Antibody OT-A201 As Monotherapy and in Combination Therapy in Patients with Selected Hematological Malignancies and Solid Tumors

Trial Profile

A First-in-human, Dose-escalation Followed by Expansion Study to Assess the Safety and Preliminary Efficacy of a Bispecific Antibody OT-A201 As Monotherapy and in Combination Therapy in Patients with Selected Hematological Malignancies and Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Lenalidomide (Primary) ; OTA 201 (Primary) ; Paclitaxel (Primary) ; Pomalidomide (Primary)
  • Indications Haematological malignancies; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Onward Therapeutics

Most Recent Events

  • 24 Jan 2024 According to a Biomunex Pharmaceuticals media release, the first patient has been enrolled in this study in 2023, thus triggered a milestone payment to Biomunex tied to the start of a Phase 1 clinical trial.
  • 27 Jun 2023 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 May 2023 to 1 Jun 2023.
  • 27 Jun 2023 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top